正在加载公司
Just reported
Q3 2026 results
From Zoetis's results release of 2026年11月5日; its quarterly report has since been filed.
Revenue
Actual
US$2.39B
-1.3% y/y
-3.1% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$1.44
-12% y/y
-13% q/qGuided
—
No guide given
EPS, adjusted: US$1.75
Company outlook
Full year 2026
- RevenueUS$9.22B – US$9.32B-2.1% y/y Raised +0.5%
- EPS, adjustedUS$6.25 – US$6.35Raised +1.6%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Zoetis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$33.5BA
NBIXNeurocrine Biosciences, Inc.US$17.6BA+
ELANElanco Animal Health IncorporatedUS$13.2BA
KNSAKiniksa Pharmaceuticals International, plcUS$8.1BA+
LQDALiquidia CorporationUS$5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
基于 Zoetis Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
